- Home
- LENZ vs IMTX Comparison
LENZ vs IMTX Comparison
Compare LENZ & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- IMTX
- Stock Information
- Founded
- LENZ 2019
- IMTX N/A
- Country
- LENZ United States
- IMTX Germany
- Employees
- LENZ N/A
- IMTX 343
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LENZ Health Care
- IMTX Health Care
- Exchange
- LENZ Nasdaq
- IMTX Nasdaq
- Market Cap
- LENZ 679.4M
- IMTX 559.1M
- IPO Year
- LENZ 2021
- IMTX N/A
- Fundamental
- Price
- LENZ $23.49
- IMTX $4.60
- Analyst Decision
- LENZ Strong Buy
- IMTX Strong Buy
- Analyst Count
- LENZ 6
- IMTX 4
- Target Price
- LENZ $35.40
- IMTX $16.67
- AVG Volume (30 Days)
- LENZ 98.3K
- IMTX 1.1M
- Earning Date
- LENZ 11-06-2024
- IMTX 03-20-2025
- Dividend Yield
- LENZ 60.66%
- IMTX N/A
- EPS Growth
- LENZ N/A
- IMTX N/A
- EPS
- LENZ N/A
- IMTX N/A
- Revenue
- LENZ N/A
- IMTX $128,824,447.00
- Revenue This Year
- LENZ N/A
- IMTX $116.22
- Revenue Next Year
- LENZ N/A
- IMTX N/A
- P/E Ratio
- LENZ N/A
- IMTX N/A
- Revenue Growth
- LENZ N/A
- IMTX 52.53
- 52 Week Low
- LENZ $2.57
- IMTX $4.48
- 52 Week High
- LENZ $38.93
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- LENZ 35.48
- IMTX 27.20
- Support Level
- LENZ $24.01
- IMTX $4.85
- Resistance Level
- LENZ $25.90
- IMTX $5.25
- Average True Range (ATR)
- LENZ 1.08
- IMTX 0.28
- MACD
- LENZ 0.02
- IMTX -0.01
- Stochastic Oscillator
- LENZ 9.02
- IMTX 8.96
About LENZ LENZ Therapeutics Inc. Common Stock
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.